2 References 1 Weiss, Jessica B., et al
Early-phase benefits set the stage for repair rather than constituting repair itself
Figure 2: Changes in body weight from baseline to the end of treatment at week 26 associated with the treatment policy estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
At Conscious Health, our providers review the regulatory status, available evidence, safety concerns, and clinical appropriateness before recommending any peptide-related treatment
AOD9604 is a peptide that is considered to be a modified fragment of growth hormone that has been shown to reduce body fat and regulate metabolism
Knowing that BPC-157 is produced in a GMP-compliant facility with testing for purity gives them added assurance